INTRODUCTION AND OBJECTIVES: Enzalutamide and abiraterone are frequently used for castration-resistant prostate cancer (CRPC), because of improved tolerability of them compared to taxanes. However, there are no predictive biomarkers to make a decision of how to best use abiraterone or enzalutamide. The aim of this study was to clarify the impact of serum testosterone in a decision-making of treatment selections (enzalutamide or abiraterone) for CRPC.
METHODS: We retrospectively evaluated consecutive CRPC patients treated at our institution and other satellite hospitals between 2013 and May 2016. A total of 115 patients received enzalutamide or abiraterone for CRPC and had serum testosterone measure at the initiation of the treatment were included in this study. The patients were divided into two groups by serum testosterone before enzalutamide or abiraterone: 54 in the testosterone <5 ng/dl group and 61 in the testosterone 5 ng/dl group. Prostate-specific antigen (PSA) response rates (defined as 50% PSA declines), PSA progression-free survival (PSA-PFS), and overall survival (OS) were compared between groups.
RESULTS: A total of 72 patients were treated with enzalutamide and 43 with abiraterone. In the testosterone <5 ng/dl group, the PSA response rates were significantly lower with enzalutamide than that with abiraterone (32% vs. 62%, p¼0.033), whereas there was no difference in the testosterone 5 ng/dl group (81% vs. 93%, p¼0.429). During the median follow-up period of 12 months, 68 men (59%) had PSA relapse. In the testosterone <5 ng/dl group, the median PSA-PFS was significantly lower with enzalutamide than that with abiraterone (2.8 months vs. 6.4 months, p¼0.004) ( Figure) . Likewise, it was significantly lower with enzalutamide than that with abiraterone in the testosterone 5 ng/dl group (7.6 months vs. no available, p¼0.004) (Figure) . Multivariate analysis reveals that testosterone 5 ng/dl was an independent predictive factor for PSA-PFS (HR 3.1, p<0.001). However, there was no significant difference in the median OS according to the different testosterone groups.
CONCLUSIONS: This result suggests that serum testosterone level is a useful biomarker in a decision-making of treatment selections in the novel hormonal therapy for CRPC. 
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INTRODUCTION AND OBJECTIVES:
We investigated whether lower testosterone threshold compared to traditionally accepted level of castrate-level testosterone (< 50 ng/dl) has an impact on time to progression to castrate-resistant prostate cancer (CRPC) in patients undergoing continuous androgen deprivation therapy (ADT).
METHODS: A single-center, prospective review of 153 consecutive patients undergoing ADT from 2006 to 2016 was performed. Patients were excluded from the analysis if they received intermittent ADT, concurrent ADT with external beam radiation therapy, or if they did not achieve castrate-level testosterone (< 50 ng/dl). Serum testosterone was measured every three months after initiation of ADT. Patients were categorized based on their 1-year mean testosterone value (< 20 ng/dl, 20-32 ng/dl, 32-50 ng/dl, > 50 ng/dl) and outcome measures were compared. Progression to CRPC was assessed with the Kaplan-Meier method. Statistical analysis was performed using the log-rank, Breslow, and Tarone-Ware tests to compare the groups.
RESULTS: A total of 112 patients were included in the analysis. Median age at diagnosis was 67.9 (range: 50.9-89.1). Median follow-up Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e713 was 27.9 months (range: 3.3-114.6). Median PSA prior to initiation of ADT was 18 ng/mL (range: 0.61-2940). 72.3% of patients achieved a 1year mean T < 20 ng/dl; 18.6% achieved 20-32 ng/dl; 5.4% achieved 32-50 ng/dl; and 3.6% achieved > 50 ng/dl. There was no statistically significant difference in progression-free survival between patients with different levels of 1-year mean testosterone values (log-rank p¼0.813). CONCLUSIONS: The results suggest that there may not be a significant impact of strict testosterone control beyond what is considered the traditional castrate-level testosterone. However, only a small proportion of patients had 1-year testosterone > 32 ng/dl (9.0%). A larger study may reveal a beneficial role of strict testosterone reduction in the management of advanced prostate cancer. METHODS: We identified 81,579 men diagnosed with prostate cancer between 2004-2009 from the Surveillance, Epidemiology and End Results database (SEER). We then risk stratified the men based on the DAmico criteria. Those with one or more unknown tumor variables (prostate specific antigen, T stage and/or Gleason Score) were labeled unknown. Of this group, we identified 2370 men who received chemotherapy after ADT, 2137 non-Hispanic Caucasian and non-Hispanic 233 African American. Overall and risk-stratified analyses were performed using T-test and multiple linear regression which compared the time interval from diagnosis to chemotherapy and from initiation of ADT to initiation of chemotherapy in African Americans vs. Caucasians.
Source of Funding: None
RESULTS: The median time from diagnosis to chemotherapy was 32 months and from initiation of ADT to chemotherapy was 25 months. The median time from ADT to chemotherapy for the low risk group was 16 months (n¼ 119), intermediate risk was 29 months (n ¼ 313), high risk 29 months (n ¼ 920) and unknown 21 months (n ¼ 1018). African American males had a median length of 18 months compared to Caucasian males 25 months (p value from t-test ¼ 0.006). After adjusting for age, year of diagnosis, income, education, Charlson comorbidity score, and risk of prostate cancer, the difference is still significant: the least squares mean time from ADT to chemo is 22.5 months in AA vs. 27.5 months in CA (p¼0.006).
CONCLUSIONS: The length of time from ADT to salvage chemotherapy in African American males is shorter compared to Caucasian males. This may suggest that AA men have cancers that progress faster on ADT compared to prostate cancer in Caucasian men. Fernando Estrada*, Angel García de Jal on, Angel Borque, Luis Esteban, Ma Jes us Gil, Gerardo Sanz, Zaragoza, Spain INTRODUCTION AND OBJECTIVES: Chemical castration (Total Testosterone, TT,<0,50 ng/mL) is common treatment in intermediate/high risk prostate cancer (PCa) adjuvant to radiotherapy, and in advanced/metastatic PCa. After androgen deprivation therapy (ADT) we assume variability and delay until recovery over castration and/or eugonadic state (TT>3.5 ng/mL). We evaluate variability, associated factors, and the design of nomograms for TT recovery after ADT withdrawal.
METHODS: Ambispective study on 205 patients after ADT cessation. Predictive variables: age at initiation/cessation of ADT, biopsy/ surgical specimen (in case) Gleason score, duration of ADT, primary therapy of PCa, and LHRH agonist. 1-107 months). We find high individualised variabilty in TT recovery.-Recovery over castration levels: 25% of patients do not recover. Our intervals of recovery for 25, 50, 75 and 100% of recoverer patients are 4, 7, 10 and 42 months.-Recovery over eugonadic levels: 84% of patients do not normalize TT. After 12 months of ADT withdrawal only 8% of patients recovered normal levels, the maximum rate of recovery is at 32 months, no one patient recovered later on. In multivariate analysis "duration of ADT" and "age at ADT withdrawal" are significant predictors (H.R: 0.69, p¼0.0002 and HR: 0.44, p<0.0001, for 0.5-Recovery; and HR:0.45,p¼0.0006 and HR:0.39,p¼0.0002, for 3.5-Recovery). We build two nomograms of recovery at 1, 2 and 3 years, with light overestimation for intermediate values in calibration analysis and a discrimination capacity ('c index') of 0.709 and 0.723, with AUC of 0.778, 0.813 and 0.805, and 0.707, 0.788 and 0.811 at 1, 2, and 3 years, respectively. CONCLUSIONS: We confirmed a high variability in TT recovery after ADT withdrawal. We found as the most relevant predictors "duration of ADT" and "age at ADT withdrawal". We obtained accurate calibrated and discriminative predictive nomograms of castration and eugonadic recovery. Those models would allow us to estimate and counsell functional recovery after adjuvant therapy, and to keep castration after ADT withdrawal or intermittency in a more cost-effectiveness practice. 
